Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• Diabetic patients face high cardiovascular event rates, with risk correlating to HbA1c levels.
• Lowering HbA1c shows less benefit for macrovascular than microvascular endpoints.
• The cardiovascular risk profiles of glucose-lowering regimens are a key clinical consideration.

Purpose of the Study:

• To review completed cardiovascular outcome trials (CVOTs) of glucose-lowering medications.
• To suggest a treatment algorithm based on cardiac and renal comorbidities.
• To translate CVOT findings into clinical practice for managing type 2 diabetes.

Main Methods:

• Review of placebo-controlled cardiovascular outcome trials (CVOTs).
• Analysis of trial results for DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors.
• Synthesis of mechanistic studies and clinical trial data.

Main Results:

• CVOTs for DPP-4 inhibitors showed general disappointment regarding cardiovascular safety.
• EMPA-REG Outcome (empagliflozin) and LEADER (liraglutide) trials demonstrated significant reductions in 3-point MACE and mortality.
• The cardioprotective effects of GLP-1 receptor agonists are mechanistically supported, while SGLT2 inhibitors' ability to prevent cardiovascular death requires further investigation.

Conclusions:

• Glucose-lowering medications have varying cardiovascular risk profiles.
• SGLT2 inhibitors and GLP-1 receptor agonists show promise in reducing cardiovascular events and mortality in type 2 diabetes.
• A treatment algorithm incorporating cardiac and renal comorbidities can optimize patient management based on CVOT findings.